CHRS Coherus BioSciences Inc.

9.73
-0.25  -3%
Previous Close 9.98
Open 9.92
Price To Book 54.06
Market Cap 661883231
Shares 68,024,998
Volume 650,017
Short Ratio
Av. Daily Volume 803,084

SEC filingsSee all SEC filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 181170169
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169883
  3. 8-K - Current report 181169739
  4. 8-K - Current report 181157006
  5. 8-K - Current report 181088075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing originally due towards the end of 2Q 2017. BLA filing still planned - timeline TBC.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar

SEC Filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 181170169
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169883
  3. 8-K - Current report 181169739
  4. 8-K - Current report 181157006
  5. 8-K - Current report 181088075
  6. CT ORDER - Confidential treatment order 181027548
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001601
  8. 8-K - Current report 181001438
  9. 8-K - Current report 18981157
  10. 8-K - Current report 18956573